MCID: NRR001
MIFTS: 43

Neuroretinitis

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Neuroretinitis

MalaCards integrated aliases for Neuroretinitis:

Name: Neuroretinitis 12 15 71
Juxtapapillary Focal Retinitis and Retinochoroiditis 12 71
Retinitis 43 71
Focal Retinitis and Retinochoroiditis, Juxtapapillary 12
Papilloretinitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10176
MeSH 43 D012173
ICD10 32 H30.9
UMLS 71 C0035333 C0154874 C3665438

Summaries for Neuroretinitis

MalaCards based summary : Neuroretinitis, also known as juxtapapillary focal retinitis and retinochoroiditis, is related to central retinal artery occlusion and retinitis pigmentosa 48. An important gene associated with Neuroretinitis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Visual Cycle in Retinal Rods and IL12 signaling mediated by STAT4. The drugs Prednisone and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and bone, and related phenotype is homeostasis/metabolism.

Wikipedia : 74 Cat-scratch disease (CSD) is an infectious disease that results from a scratch or bite of a cat.... more...

Related Diseases for Neuroretinitis

Diseases related to Neuroretinitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2985)
# Related Disease Score Top Affiliating Genes
1 central retinal artery occlusion 34.2 CRP CD40LG
2 retinitis pigmentosa 48 34.1 SAG CD40LG
3 macular dystrophy, dominant cystoid 32.8 RCVRN MRAP ACE
4 macular retinal edema 30.9 MRAP ACE
5 eales disease 30.8 SAG IFNG
6 retinal vasculitis 30.7 SAG MRAP CD40LG ACE
7 cancer-associated retinopathy 30.6 SAG RCVRN
8 purpura 30.6 CRP CD40LG ACE
9 toxocariasis 30.5 MRAP CRP CD40LG
10 hypertensive retinopathy 30.4 CRP ACE
11 fuchs' heterochromic uveitis 30.4 MRAP ACE
12 asymptomatic neurosyphilis 30.3 CD40LG CD4
13 cat-scratch disease 30.3 CS CRP CD40LG CD4 ACE
14 patent foramen ovale 30.2 CRP CD40LG ACE
15 boutonneuse fever 30.2 CS CD40LG
16 secondary syphilis 30.2 CD40LG CD4
17 cholesterol embolism 30.2 CRP ACE
18 subacute bacterial endocarditis 30.1 CRP CD40LG
19 acquired immunodeficiency syndrome 30.1 IFNG CRP CD40LG CD4
20 enthesopathy 30.1 MRAP CRP
21 spondyloarthropathy 1 30.0 MRAP CRP CD40LG
22 tolosa-hunt syndrome 30.0 CRP ACE
23 interstitial nephritis 30.0 CRP CD40LG ACE
24 pulmonary embolism 30.0 CRP CD40LG ACE
25 intracranial embolism 30.0 CRP ACE
26 leptospirosis 30.0 IFNG CRP CD40LG
27 papilledema 30.0 CRP CD40LG CD4 ACE
28 bacillary angiomatosis 30.0 CS CD4
29 congenital toxoplasmosis 29.9 CD40LG CD4
30 cysticercosis 29.9 CD40LG CD4
31 coccidioidomycosis 29.9 CD40LG CD4
32 relapsing-remitting multiple sclerosis 29.9 IFNG CD40LG AQP4
33 rocky mountain spotted fever 29.9 CS CD40LG
34 polyneuropathy 29.9 CRP CD40LG ACE
35 acute retinal necrosis syndrome 29.9 MRAP CD40LG CD4
36 posterior scleritis 29.9 MRAP CRP ACE
37 cellulitis 29.9 CRP CD40LG CD4
38 granulomatous angiitis 29.9 CRP ACE
39 arteriosclerosis 29.9 IFNG CRP ACE
40 orbital disease 29.8 CRP CD40LG
41 cerebral atherosclerosis 29.8 CRP ACE
42 coronary artery anomaly 29.7 CRP CD40LG CD4 ACE
43 nocardiosis 29.7 CRP CD4
44 aortic valve insufficiency 29.7 MRAP CRP ACE
45 good syndrome 29.7 CRP CD40LG CD4
46 interval angle-closure glaucoma 29.7 RCVRN CRP
47 latent syphilis 29.7 CD40LG CD4
48 portal hypertension 29.7 CD40LG CD4 ACE
49 posterior uveitis 29.7 SAG MRAP IFNG
50 syphilis 29.7 MRAP CRP CD40LG CD4 ACE

Graphical network of the top 20 diseases related to Neuroretinitis:



Diseases related to Neuroretinitis

Symptoms & Phenotypes for Neuroretinitis

MGI Mouse Phenotypes related to Neuroretinitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.28 ACE AQP4 CD4 CD40LG CRP CS

Drugs & Therapeutics for Neuroretinitis

Drugs for Neuroretinitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 225)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azithromycin Approved Phase 4 83905-01-5 55185 447043
3
Sodium citrate Approved, Investigational Phase 4 68-04-2
4
Ranibizumab Approved Phase 4 347396-82-1 459903
5
Pancrelipase Approved, Investigational Phase 4 53608-75-6
6
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
7 Antineoplastic Agents, Hormonal Phase 4
8 Sildenafil Citrate Phase 4 171599-83-0
9 Citrate Phase 4
10 Antibodies Phase 4
11 Immunoglobulins Phase 4
12 Gastrointestinal Agents Phase 4
13 Angiogenesis Inhibitors Phase 4
14 Autoantibodies Phase 4
15 Vardenafil Dihydrochloride Phase 4
16 Vasodilator Agents Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Phosphodiesterase 5 Inhibitors Phase 4
19 pancreatin Phase 4
20
Eplerenone Approved Phase 2, Phase 3 107724-20-9 150310 443872
21
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
22
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
23
Acyclovir Approved Phase 3 59277-89-3 2022
24
Ganciclovir Approved, Investigational Phase 2, Phase 3 82410-32-0 3454
25
Valganciclovir Approved, Investigational Phase 2, Phase 3 175865-60-8 64147
26
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
27
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
28
Lutein Approved, Investigational, Nutraceutical Phase 3 127-40-2 6433159
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
30 Tocotrienol Investigational Phase 3 6829-55-6
31 Hormone Antagonists Phase 2, Phase 3
32 Hormones Phase 2, Phase 3
33 Mineralocorticoids Phase 2, Phase 3
34 Mineralocorticoid Receptor Antagonists Phase 2, Phase 3
35 Natriuretic Agents Phase 2, Phase 3
36 Diuretics, Potassium Sparing Phase 2, Phase 3
37 diuretics Phase 2, Phase 3
38 Immunologic Factors Phase 3
39 Antibodies, Monoclonal Phase 2, Phase 3
40 Antineoplastic Agents, Immunological Phase 2, Phase 3
41 retinol Phase 3
42 Retinol palmitate Phase 3
43 Tocopherols Phase 3
44 Tocotrienols Phase 3
45 Calciferol Phase 3
46 Antiviral Agents Phase 2, Phase 3
47 Anti-Infective Agents Phase 2, Phase 3
48 Ganciclovir triphosphate Phase 2, Phase 3
49 Antihypertensive Agents Phase 3
50 Isopropyl unoprostone Phase 3

Interventional clinical trials:

(show top 50) (show all 262)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease Unknown status NCT01469702 Phase 4 prednison and azithromycin;prednison, azithromycin;prednison, Azenil
2 A Prospective, Randomized, 3-arm Parallel Trial to Evaluate the Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Treatment Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
3 Role of Capsular Tension Ring in Anterior Capsular Contraction in Retinitis Pigmentosa Patients Completed NCT00717080 Phase 4
4 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
5 Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000894 Phase 4 Cidofovir;Probenecid;Ganciclovir
6 Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration Completed NCT01866397 Phase 4
7 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
8 Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial Completed NCT02843490 Phase 4 Ranibizumab
9 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
10 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
11 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
12 Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment Unknown status NCT00017784 Phase 3 Valganciclovir
13 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
14 Foscarnet-Ganciclovir CMV Retinitis Trial Completed NCT00000136 Phase 3 Foscarnet;Ganciclovir
15 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
16 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
17 A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes Completed NCT00002377 Phase 3 Valganciclovir;Ganciclovir
18 Cytomegalovirus Retinitis Retreatment Trial Completed NCT00000134 Phase 3 Ganciclovir;Foscarnet
19 Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) Completed NCT00000142 Phase 2, Phase 3 Cidofovir
20 Monoclonal Antibody CMV Retinitis Trial (MACRT) Completed NCT00000135 Phase 2, Phase 3 MSL-109
21 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
22 Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT) Completed NCT00000143 Phase 3 Cidofovir intravenous
23 Ganciclovir Implant Study for Cytomegalovirus Retinitis Completed NCT00000118 Phase 3
24 Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa Completed NCT00000114 Phase 3 Vitamin E;Vitamin A
25 Randomized Clinical Trial for Retinitis Pigmentosa Completed NCT00346333 Phase 3 Lutein
26 Randomized Trial for Retinitis Pigmentosa Completed NCT00000116 Phase 3 Vitamin A;Nutritional Supplement
27 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
28 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
29 A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) Recruiting NCT03116113 Phase 2, Phase 3
30 The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa Recruiting NCT01680510 Phase 2, Phase 3
31 Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Recruiting NCT03586284 Phase 2, Phase 3 Valganciclovir Hydrochloride;Ganciclovir Sodium;Placebo Oral Tablet;Topical placebo
32 A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301] Active, not recruiting NCT00999609 Phase 3
33 Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period Terminated NCT01786395 Phase 3 UF-021;Placebo
34 Argus® II Retinal Stimulation System Feasibility Protocol Unknown status NCT00407602 Phase 2
35 An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01914913 Phase 1, Phase 2
36 Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) Unknown status NCT02661711 Phase 2 Aflibercept
37 Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema Unknown status NCT02804360 Phase 2
38 A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection Completed NCT00002169 Phase 2 Nelfinavir mesylate
39 Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial Completed NCT02609165 Phase 2 rhNGF 180 µg/ml eye drops solution;vehicle eye drops
40 Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa Completed NCT01399515 Phase 2 Valproic Acid
41 A Phase II/III Study of the Safety and Efficacy of 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) for the Treatment of Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00002437 Phase 2 Cidofovir;Probenecid
42 A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) Completed NCT00000836 Phase 2 Sevirumab
43 An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa Completed NCT00661479 Phase 1, Phase 2 400 µg Brimonidine Tartrate Implant;200 µg Brimonidine Tartrate Implant;100 µg Brimonidine Tartrate Implant
44 CMV Retinitis Retreatment Trial Completed NCT00000766 Phase 2 Foscarnet sodium;Ganciclovir
45 An Open-Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients With Cytomegalovirus Retinitis (NOTE: Restricted to Patients Who Rollover From Another Controlled ISIS 2922 Trial) Completed NCT00002356 Phase 2 Fomivirsen sodium
46 A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR ) Completed NCT00002156 Phase 2 Fomivirsen sodium;Ganciclovir
47 A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa Completed NCT01233609 Phase 2 Valproic Acid;Placebo
48 Phase II Randomized Study of Cidofovir for Peripheral Cytomegalovirus Retinitis Completed NCT00004794 Phase 2 cidofovir
49 A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP) Completed NCT02320812 Phase 1, Phase 2
50 A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis Completed NCT00001061 Phase 2 Sevirumab;Foscarnet sodium;Ganciclovir

Search NIH Clinical Center for Neuroretinitis

Cochrane evidence based reviews: retinitis

Genetic Tests for Neuroretinitis

Anatomical Context for Neuroretinitis

MalaCards organs/tissues related to Neuroretinitis:

40
Retina, Eye, Bone, Testes, T Cells, Brain, Kidney

Publications for Neuroretinitis

Articles related to Neuroretinitis:

(show top 50) (show all 12293)
# Title Authors PMID Year
1
Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies, particularly neurodegenerative retinal diseases. 61
31997799 2020
2
Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant mRNA Expression Profiles. 61
31909088 2020
3
Parthanatos-associated proteins are stimulated intraocularly during development of experimental murine cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression. 61
31670405 2020
4
(Z)-7,4'-Dimethoxy-6-hydroxy-aurone-4-O-β-glucopyranoside mitigates retinal degeneration in Rd10 mouse model through inhibiting oxidative stress and inflammatory responses. 61
31648555 2020
5
Cytomegalovirus disease in a retinoblastoma cohort: The role of preemptive screening. 61
31793213 2020
6
Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa. 61
31810025 2020
7
Bilateral retinitis after influenza virus infection in a case report. 61
31956727 2020
8
Expanding the phenotypic spectrum in RDH12-associated retinal disease. 61
32014858 2020
9
Successful treatment of an AIDS patient with prolonged Mycobacterium avium bacteremia, high HIV RNA, HBV infection, Kaposi's sarcoma and cytomegalovirus retinitis. 61
31543435 2020
10
Clinical Features of Ocular Syphilis: a Retrospective Clinical Study in an Italian Referral Centre. 61
32036734 2020
11
Posterior column ataxia with retinitis pigmentosa (PCARP) in an Iranian patient associated with the FLVCR1 gene. 61
32039643 2020
12
Barriers in utilisation of low vision assistive products. 61
31388131 2020
13
Retinitis pigmentosa prior to familial ALS caused by a homozygous cilia and flagella-associated protein 410 mutation. 61
31431468 2020
14
Rhodopsin Genomic Loci DNA Nanoparticles Improve Expression and Rescue of Retinal Degeneration in a Model for Retinitis Pigmentosa. 61
31879189 2020
15
A c.544_618del75bp mutation in the splicing factor gene PRPF31 is involved in non-syndromic retinitis pigmentosa by reducing the level of mRNA expression. 61
32031697 2020
16
Toxicity and Efficacy Evaluation of an Adeno-Associated Virus Vector Expressing Codon-Optimized RPGR Delivered by Subretinal Injection in a Canine Model of X-linked Retinitis Pigmentosa. 61
31910043 2020
17
ER complex proteins are required for rhodopsin biosynthesis and photoreceptor survival in Drosophila and mice. 61
31263175 2020
18
The functional impact of the C/N-terminal extensions of the mouse retinal IMPDH1 isoforms: a kinetic evaluation. 61
31838626 2020
19
Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration. 61
32028070 2020
20
Clinical-grade production and safe delivery of human ESC derived RPE sheets in primates and rodents. 61
31732225 2020
21
Retinal vascular inflammatory and occlusive changes in infectious and non-infectious uveitis. 61
32016664 2020
22
Permanent visual work disabilities: 321 cases review. 61
32035740 2020
23
[Retinitis pigmentosa]. 61
32030928 2020
24
Sector retinitis pigmentosa. 61
31948687 2020
25
New Nrf2-Inducer Compound ITH12674 Slows the Progression of Retinitis Pigmentosa in the Mouse Model rd10. 61
32028545 2020
26
Phenotypic expansion of autosomal dominant retinitis pigmentosa associated with the D477G mutation in RPE65. 61
32014860 2020
27
RNA Splicing Factor Mutations That Cause Retinitis Pigmentosa Result in Circadian Dysregulation. 61
31726916 2020
28
Expanding the retinal phenotype of RP1: from retinitis pigmentosa to a novel and singular macular dystrophy. 61
31079053 2020
29
Retinitis Pigmentosa Associated with Bardet-Biedl Syndrome with BBS9 Gene Mutation in a Korean Patient. 61
32037757 2020
30
Thiol/disulfide homeostasis in retinitis pigmentosa patients. 61
32024375 2020
31
Novel REEP6 gene mutation associated with autosomal recessive retinitis pigmentosa. 61
31538292 2020
32
Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema. 61
31676123 2020
33
A novel missense variant in the BBS7 gene underlying Bardet-Biedl syndrome in a consanguineous Pakistani family. 61
31469663 2020
34
Multiple genetic mutations implicate spectrum of phenotypes in Bardet-Biedl syndrome. 61
31639430 2020
35
A retinitis punctata albescens family with biallelic mutations in retinaldehyde-binding Protein 1. 61
32001820 2020
36
A founder RDH5 splice site mutation leads to retinitis punctata albescens in two inbred Pakistani kindreds. 61
31933420 2020
37
A NOVEL LARGE HOMOZYGOUS DELETION IN THE CELLULAR RETINALDEHYDE-BINDING PROTEIN GENE (RLBP1) IN A PATIENT WITH RETINITIS PUNCTATA ALBESCENS. 61
28827498 2020
38
RPGR-Associated Dystrophies: Clinical, Genetic, and Histopathological Features. 61
32012938 2020
39
A nationwide genetic analysis of inherited retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC). 61
31456290 2020
40
Lack of PDZD7 long isoform disrupts ankle-link complex and causes hearing loss in mice. 61
31914662 2020
41
Xanthophyll: Health benefits and therapeutic insights. 61
31783054 2020
42
The majority of autosomal recessive nanophthalmos and posterior microphthalmia can be attributed to biallelic sequence and structural variants in MFRP and PRSS56. 61
31992737 2020
43
Enigmatic rhodopsin mutation creates an exceptionally strong splice acceptor site. 61
31816042 2020
44
Developing a simple method to enhance the generation of cone and rod photoreceptors in pluripotent stem cell-derived retinal organoids. 61
31670434 2020
45
Cytomegalovirus enteritis with intractable diarrhea in infants from a tertiary care center in China. 61
31917930 2020
46
Tofacitinib-associated cytomegalovirus retinitis. 61
31990341 2020
47
Association of retinal biomarkers and choroidal vascularity index on optical coherence tomography using binarization method in retinitis pigmentosa. 61
31713751 2020
48
Mimicking of splicing-related retinitis pigmentosa mutations in C. elegans allow drug screens and identification of disease modifiers. 61
31919495 2020
49
Identification of 13 novel USH2A mutations in Chinese retinitis pigmentosa and Usher syndrome patients by targeted next-generation sequencing. 61
31904091 2020
50
Degenerated Cones in Cultured Human Retinas Can Successfully Be Optogenetically Reactivated. 61
31947650 2020

Variations for Neuroretinitis

Expression for Neuroretinitis

Search GEO for disease gene expression data for Neuroretinitis.

Pathways for Neuroretinitis

Pathways related to Neuroretinitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 SAG RCVRN CRP
2 10.4 IFNG CD4

GO Terms for Neuroretinitis

Cellular components related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40LG CD4 AQP4 ACE

Biological processes related to Neuroretinitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of interleukin-12 production GO:0032735 8.62 IFNG CD40LG

Sources for Neuroretinitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....